USA, a subsidiary of Revlon. Our product offering today includes Active Pharmaceutical Ingredients (APIs), Fixed Dosages Formulations (FDF), Peptides, Biosimilars and Injectables. These are manufactured in our cGMP compliant plants located in India. We market our products globally to 65 countries. In the financial year 2018-19, our total income was Rs 31,065 million. Our Indian business contributed 83% to the revenue and the rest was from export of APIs and Finished Dosages.
source https://www.pharmatutor.org/content/march-2020/walk-in-interview-for-mpharm-msc-bpharm-in-quality-control-assurance-production-warehouse-at-usv-pvt-ltd
No comments:
Post a Comment